Live feed
·
PRReleasevia Quantisnow
FSD Pharma Inc. logo

FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

ByQuantisnow·Wall Street's wire, on your screen.
HUGE· FSD Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HUGE (FSD Pharma Inc.) and more on Quantisnow.